ClinicalTrials.gg
Not yet recruitingNCT06099990Updated Oct 25, 2023

Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

A Phase 1 interventional study of dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets and placebo; abiraterone acetate tablets; prednisone tablets in High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC), sponsored by Jiangsu HengRui Medicine Co., Ltd.. Not yet recruiting. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-25.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
660
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

This study was to evaluate the safety and efficacy of dalcilide tablets in combination with AA-P in the treatment of subjects with high tumor burden mHSPC and to determine the second stage starting dose and progression-free survival(rPFS) based on BICR assessment

02

Conditions studied

  • High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

Browse trials for

03

In context

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.

This study's planned enrollment of 660 is above the median of 50 across 3,270 interventional studies indexed under Neoplasm Metastasis.

Browse Neoplasm Metastasis studies →

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age of ≥ 18 years old,male
  2. PS score of 0 or 1;
  3. Prostate adenocarcinoma confirmed by histological。
  4. ADT no more than 3 months prior to randomization (when docetaxel is not used) with no radiographic or PSA progression
  5. Receiving or maintaining androgen deprivation therapy (ADT) during the planned study period, i.e. continuous treatment with luteinizing hormone-releasing hormone analogues (LHRHA) (drug castration) or prior bilateral orchiectomy (surgical castration)
  6. Voluntarily participate in this clinical trial, understand the study procedure and have signed

Exclusion criteria

Exclusion Criteria:

  1. Previous ADT, chemotherapy, surgery, external radiation exposure, brachytherapy, radiopharmaceuticals, or experimental topical treatments (eg, radiofrequency ablation, cryoponic, high-energy focused ultrasound) for prostate cancer
  2. Previous use of CDK4/6 inhibitors (such as piperaciclib, rebocillib and abeceptil), second-generation androgen receptor antagonists (such as enzalutamide, apatamide, darotamide, revilumide and proclomide, etc.), ketoconazole, abiraterone acetate or other drugs that inhibit androgen synthesis (such as TAK-700), other anti-tumor biological therapy, targeted therapy or tumor immunotherapy
  3. Confirmed by imaging, there are brain tumor foci
  4. History of severe lung disease such as interstitial pneumonia
  5. Plan to receive any other antitumor therapy during this trial
  6. Inability to swallow, chronic diarrhea and intestinal obstruction, or other factors that affect drug taking and absorption
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
660 participants (estimated)

Study arms

  • Experimental
    dalpiciclib+ abiraterone+ prednisone

    Drug: dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets

  • Placebo comparator
    placebo+abirarerone+prenisone

    Drug: placebo; abiraterone acetate tablets; prednisone tablets

Interventions

  • Drugdalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets

    Drug pages: Dalpiciclib isethionate · Abiraterone Acetate · Prednisone

    dalpiciclib+ abiraterone+ prednisone

  • Drugplacebo; abiraterone acetate tablets; prednisone tablets

    placebo+abirarerone+prenisone

06

What researchers measure

Primary outcomes

  1. Adverse event (AE) incidence

    Time frame: approximately 63 months

Secondary outcomes

  1. PK: Steady-state trough concentrations of Dalsili and Abiraterone (Cmin, ss)

    Time frame: approximately 6 months

  2. rPFS

    Time from randomisation to radiologically confirmed progressive disease or death due to any cause

    Time frame: approximately 63 months

  3. PSA response rate

    In patients who had not started androgen deprivation prior to randomization, the proportion of patients whose PSA levels were ≥ 90% lower than baseline by the end of the study treatment week

    Time frame: approximately 63 months

  4. ORR

    Objective response rate+ The proportion of participants evaluated according to RECIST v1.1 and PCWG3 criteria that achieved predetermined tumor volume reduction and maintained the minimum duration was the sum of the proportion of complete and partial responses

    Time frame: approximately 63 months

  5. Time to PSA progression

    Time from randomisation to the first time of PSA progression

    Time frame: approximately 63 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2023; primary completion for Dec 2028, 62 months later.

Of 286 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 62 months is above that.

Counting every sponsor, half of 496 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2023
First posted
Oct 25, 2023
StartEst.
Oct 2023
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Oct 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06099990
Responsible party
Sponsor
First posted
Oct 25, 2023
Start date
Oct 2023 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 25, 2023

Study contacts

Feng Liu
Contact
feng.liu.fl10@hengrui.com
+86-18875033874

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dalpiciclib isethionate · Abiraterone Acetate · Prednisone

Start the discussion